<DOC>
	<DOCNO>NCT00085631</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Hyperthermia therapy kill tumor cell heat several degree body temperature . It yet know whether chemotherapy radiation therapy effective without hyperthermia therapy treat cervical cancer . PURPOSE : This randomized phase III trial compare safety efficacy cisplatin radiation therapy , together hyperthermia therapy versus cisplatin radiation therapy alone treatment locally advanced cervical cancer .</brief_summary>
	<brief_title>Cisplatin Radiation Therapy With Without Hyperthermia Therapy Treating Patients With Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : Compare local control , failure-free survival , overall survival patient locally advance carcinoma cervix treat cisplatin radiotherapy alone , versus cisplatin radiotherapy hyperthermia . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , disease stage ( IIB IIIA v IIIB IVA ) age ( &lt; 60 year vs ≥ 60 year ) . Patients randomize 1 2 treatment arm . LIMITATIONS : There integrity issue currently available data , involve international institution , several piece information relate patient accrual outcome verify . Therefore , would inappropriate report outcome measure study . Baseline measure age gender report entire study cohort . Participant flow report treatment arm assignment , available majority patient currently available data . Adverse event report entire cohort , adverse event could classify within particular treatment arm .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion : Invasive cervical carcinoma ( squamous , adeno adenosquamous histology , small cell histology exclude ) age &gt; 18years International Federation Gynecology Obstetrics ( ( FIGO ) stage IB2 , IIAIVA , FIGO stag IA , IB1 positive pelvic lymph node parametria either image technique pathologically involved time surgery . patient undergo surgical removal cervix uterus eligible , parametria either image technique pathologically involved time • Performance status Eastern Cooperative Oncology Group ( ECOG ) /World Health Organisation ( WHO ) 0 , 1 &gt; /=70 % respectively White Blood count ( WBC ) ≥ 3,000 , platelet ≥ 100,000 , Absolute Neutrophil Count ( ANC ) &gt; 1500 • serum bilirubin ≤ 1.5 time upper limit normal , transaminase ≤ 3 time upper limit normal calculated creatinine clearance &gt; 60milliliters ( ml ) /liter ( Cockcroft ) OR creatinine &lt; /= 2.0mgs % paraaortic adenopathy absent 1.5 centimeter ( cm ) great dimension Computerised Tomography ( CT ) Magnetic Resonance Imaging ( MRI ) scan ; No history myocardial infarction last 6 month symptomatic angina pectoris negative pregnancy test patient 50 Hemoglobin &gt; 12.0 Gd/dl &gt; 7.5 mmo ; /L transfusion need write write informed consent Exclusion criterion : surgical resection primary tumor ( i.e . Total abdominal hysterectomy ( TAH ) / Bilateral salpingoophorectomy ( BSO ) patient pacemaker implanted defibrillator patient significant metallic foreign body ( i.e . hip replacement , bone metallic rod , orthopedic plate , etc . ) prior radiotherapy chemotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage IA cervical cancer</keyword>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
</DOC>